Reports
Sale
Global Breast Cancer Treatment Market Share, Size, Growth, Analysis, Report, Trends, Forecast: By Diagnosis: Imaging, Biopsy, Genomic Tests, Blood Tests, Others; By Therapy: Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy, Others; By Indication; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Breast Cancer Treatment Market Outlook
The global breast cancer treatment market size attained a value of USD 20.43 billion in 2022. The market is likely to grow at a rate of 10.10% during the forecast period of 2023-2031. The market growth is driven by the growing demand for diagnostics and therapeutics and the market is anticipated to be worth USD 49.07 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Breast Cancer: Types, Causes, Diagnosis, and Treatment
Breast cancer is the abnormal cell growth in and around the breast region. Breast cancer is of several types, depending on the breast cells that are converted into cancerous ones. Most of the breast cancers begin in the ducts or lobules of the breast and then eventually spread to the other surrounding regions.
The two most common types of breast cancer are invasive ductal carcinoma and invasive lobular carcinoma. The breast cancer is classified as metastasized when it spread outside to the other parts of the body. The common clinical manifestations of breast cancer include formation of new lumps, breast thickening, skin irritation, redness in the nipple area, and pain in the breast area.
The diagnosis of breast cancer can be performed with the help of additional tests including breast ultrasound, diagnostic mammogram, breast magnetic resonance imaging, and biopsy. The precise and accurate diagnosis is essential to determine the cancer staging, in order to provide the related treatment and management.
There are different treatment regimens for the eradication of breast cancer. This includes surgery, chemotherapy, hormonal therapy, biological therapy, and radiation therapy. These therapeutic interventions will aid in removing the cancerous lumps and controlling the spreadability of cancerous cells to the other organs.
The breast cancer treatment market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis
- Imaging
- Biopsy
- Genomic Tests
- Blood Tests
- Others
Market Breakup by Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
- Chemotherapy
- Immunotherapy
- Others
Breast Cancer Treatment Market Breakup by Indication
- Invasive Ductal Carcinoma
- Invasive Lobular Carcinoma
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Scenario
The growth of the breast cancer treatment market is driven by the increasing prevalence and incidence of breast cancer in both developing and developed nations. According to the Cancer Australia, in 2021, the risk of breast cancer was estimated to be 1 in 15 individuals by the age of 85. Thus, the rising cases of breast cancer has directly influenced the demand for the breast cancer treatment, thereby attributing to the market growth.
The growing research and development activities by the strategic key market players are expected to accelerate the launch and development of novel therapeutic products, that will further boost the market during the forecast period. For example, in September 2021, Novartis collaborated with the SOLTI Innovative Cancer Research for performing the clinical trials for a novel therapy that has shown some promising effects for the treatment of the metastatic breast cancer with a HER2E intrinsic subtype.
The rising number of mergers and acquisitions among the major pharmaceutical companies is also expected to bolster the breast cancer treatment market growth. Recently, Pfizer and Arvinas have collaborated to develop and commercialise ARV-471, an investigational therapy, that has been effective in the management of the breast cancer.
Key Market Trends by Therapy and Region
Among the therapies, chemotherapy is anticipated to hold the maximum share in the breast cancer treatment market owing to the growing patient pool receiving chemotherapy and the novel product launches and approvals in this sector. According to the Centres for Disease Control and Prevention, nearly 650,000 patients receive chemotherapy annually in the United States.
North America is expected to dominate the market during the forthcoming period due to the increasing disease burden and raising awareness in this region. According to breastcancer.org, nearly, one in eight women develop invasive breast cancer over their lifetime in the United States. Further, the expanding research activities and advanced healthcare facilities in the region are expected to propel the breast cancer treatment market growth during the forecast period.
Therapeutic Landscape
The treatment of the breast cancer depends on the type of breast cancer, its stage, size, and the extent of spreadability in the body. The therapeutic interventions incorporate the different types of surgeries, medications, and other supporting palliative care.
Different Therapies: Radiotherapy, Chemotherapy, Immunotherapy, and Targeted Drug Therapies
The commonly used method is the surgical procedure which involves the removing of the tumour, lymph nodes, entire breast, or both breasts. The different invasive procedures used in the eradication of the breast tumours are lumpectomy, mastectomy, sentinel node biopsy, and axillary lymph node dissection.
Radiation therapy is utilised for the killing of the cancerous cells with the help of the high-powered beams of energy, such as protons and X-rays. The breast radiation therapy is generally done after the surgical interventions to kill the left-over cancerous cells if any, and usually lasts for three days to six weeks depending on the treatment scenario.
Chemotherapy is another therapy which is applied for destroying the fast-growing cancerous cells with the help of the drugs. This therapy is considered after surgery to prevent the risks of recurrence of cancer and to control the spreadability of the cancer.
Hormone therapy is incorporated in the cases, where the cancers are hormone sensitive, and are referred to as progesterone receptor positive and oestrogen receptor positive. This type of therapy can be used before or after the surgery to control and reduce the size of cancer.
Along with all the available treatment strategies, palliative care should be provided to improve the quality of life and increase the longevity of the patient.
Clinical Trials Landscape of the Breast Cancer Treatment Market
The recent discovery of novel targeted therapies has been of major interest to experts, researchers, and key players. Tremendous efforts and intensive research and development are under process for immunotherapy and tyrosine kinase inhibitors. Despite the discovery of many novel oncological agents, the focus of the scientists is to explore the optimisation of new therapeutic interventions into clinical practice.
Scientists at Tel Aviv University are developing a novel treatment, that is expected to increase the efficacy of chemotherapy in the breast cancer patients. The therapy produces a cancer promoting inflammatory environment in response to the chemotherapy, and thus, with the addition of anti-inflammatory agent, metastasis can be prevented.
An experimental breast cancer vaccine has shown promising effects in the treatment of the advanced stage ERBB2-positive breast cancer. Currently, the vaccine is under the advanced phases of clinical trials and target the receptor in the breast cancer.
Researchers from the University of Amazonia are performing the clinical trials in the animal and human models for treating the triple negative breast cancer. The drug is based on the epidermal growth factor receptor technology and is presently under Phase I clinical trials.
The significant advancements have led to the discovery of many novel therapeutic products, which are anticipated to bolster the market growth and development, once approved.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the breast cancer treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Mylan N.V (Viatris Inc.)
- AstraZeneca
- Celltrion Inc.
- Bristol-Myers Squibb Company
- Fresenius Kabi AG
- Eisai Co., Ltd.
- Baxter
- GSK plc
- Pfizer Inc.
- Halozyme, Inc.
- Novartis AG
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis |
|
| Breakup by Therapy |
|
| Breakup by Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Breast Cancer Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Breast Cancer Treatment Market
8.1 Global Breast Cancer Treatment Market Overview
8.2 Global Breast Cancer Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Breast Cancer Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Breast Cancer Treatment Market Forecast Value (2023-2031)
8.2.2 Global Breast Cancer Treatment Market by Diagnosis
8.2.2.1 Market Overview
8.2.2.1.1 Imaging
8.2.2.1.2 Biopsy
8.2.2.1.3 Genomic Tests
8.2.2.1.4 Blood Tests
8.2.2.1.5 Others
8.2.3 Global Breast Cancer Treatment Market by Therapy
8.2.3.1 Market Overview
8.2.3.1.1 Targeted Therapy
8.2.3.1.1.1 Abemaciclib
8.2.3.1.1.2 Ado-Trastuzumab Emtansine
8.2.3.1.1.3 Everolimus
8.2.3.1.1.4 Trastuzumab
8.2.3.1.1.5 Ribociclib
8.2.3.1.1.6 Palbociclib
8.2.3.1.1.7 Pertuzumab
8.2.3.1.1.8 Olaparib
8.2.3.1.1.9 Others
8.2.3.1.2 Hormonal Therapy
8.2.3.1.2.1 Selective Estrogen Receptor Modulators (SERMs)
8.2.3.1.2.2 Aromatase Inhibitors
8.2.3.1.2.3 Estrogen Receptor Downregulators (ERDs)
8.2.3.1.3 Chemotherapy
8.2.3.1.4 Immunotherapy
8.2.3.1.5 Others
8.2.4 Global Breast Cancer Treatment Market by Indication
8.2.4.1 Market Overview
8.2.4.1.1 Invasive Ductal Carcinoma
8.2.4.1.2 Invasive Lobular Carcinoma
8.2.4.1.3 Others
8.2.5 Global Breast Cancer Treatment Market by Distribution Channel
8.2.5.1 Market Overview
8.2.5.1.1 Hospital Pharmacies
8.2.5.1.2 Retail Pharmacies
8.2.5.1.3 Online Pharmacies
8.2.5.1.4 Others
8.2.6 Global Breast Cancer Treatment Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Middle East and Africa
8.2.6.1.5 Latin America
9 North America Breast Cancer Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Breast Cancer Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Breast Cancer Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Breast Cancer Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Breast Cancer Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Breast Cancer Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Mylan N.V (Viatris Inc.)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 AstraZeneca
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Celltrion Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Bristol-Myers Squibb Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Fresenius Kabi AG
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Eisai Co., Ltd.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Baxter
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 GSK plc
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Pfizer Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Halozyme, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Novartis AG
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Global Breast Cancer Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customizable as per client requirements.
Key Questions Answered in the Report
The global breast cancer treatment market size reached a value of USD 20.43 billion in 2022.
The market is likely to grow at a rate of 10.10% during the forecast period of 2023-2031 to attain a value of about USD 49.07 billion by 2031.
Based on the diagnosis, the market is segmented into imaging, biopsy, genomic tests, and blood tests, among others.
Based on the therapy, the market is categorised into targeted therapy, hormonal therapy, chemotherapy, and immunotherapy, among others.
Based on the indication, the market is segmented into invasive ductal carcinoma and invasive lobular carcinoma, among others.
Based on the distribution channel, the market is categorised into hospital pharmacies, online pharmacies, and retail pharmacies, among others.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
The key companies involved in the market are Mylan N.V (Viatris Inc.), AstraZeneca, Celltrion Inc., Bristol-Myers Squibb Company, Fresenius Kabi AG, Eisai Co., Ltd., Baxter, GSK plc, Pfizer Inc., Halozyme, Inc., and Novartis AG, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER